Want to see CNTX full AI Analyst Report?
Top Page
Context Therapeutics
(NASDAQ:CNTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.30
▼(-32.05% Downside)
Action:Reiterated
Date:09/12/26
The score is primarily held down by weak financial performance (no revenue, widening losses, and accelerating cash burn) and bearish technicals (price below all key moving averages with negative MACD). Corporate events are mixed—pipeline progress is encouraging, but the Nasdaq minimum bid notice and potential dilution risk add material uncertainty.
Positive Factors
Low Financial Leverage
Very low leverage reduces fixed financial obligations and preserves flexibility while the company advances its pipeline. Unlike a highly indebted developer, CNTX is not using substantial debt to fund operations, which limits interest-related pressure and balance-sheet risk.
Negative Factors
Pre-Revenue Business Model
CNTX has no commercial product revenue to offset research and operating costs, so its financial profile remains dependent on advancing development assets. Until a program reaches commercialization or a strategic transaction generates proceeds, operating performance will remain disconnected from sales growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low leverage reduces fixed financial obligations and preserves flexibility while the company advances its pipeline. Unlike a highly indebted developer, CNTX is not using substantial debt to fund operations, which limits interest-related pressure and balance-sheet risk.
Read all positive factors
Context Therapeutics (CNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.45M
Dividend YieldN/A
Average Volume (3M)1.44M
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue GrowthN/A
EPS Growth-23.49%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding91,879,170
10 Day Avg. Volume969,402
30 Day Avg. Volume1,441,689
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-248.36
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$3.20Price Target Upside627.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.44
Revenue Forecast (FY)N/A
Context Therapeutics Business Overview & Revenue Model
Company Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediat...
How the Company Makes Money
As a clinical-stage biotechnology company, Context Therapeutics does not have a broadly disclosed, product-based commercial revenue model in publicly available information; therefore, specific recurring revenue streams from product sales are null....
Context Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -40.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -45.91M | -36.11M | -26.71M | -23.95M | -14.87M | -10.53M |
| Net Income | -45.96M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
Balance Sheet | ||||||
| Total Assets | 46.13M | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M |
| Cash, Cash Equivalents and Short-Term Investments | 42.99M | 66.00M | 94.43M | 14.45M | 35.50M | 49.64M |
| Total Debt | 244.99K | 112.06K | 219.38K | 0.00 | 55.08K | 0.00 |
| Total Liabilities | 7.96M | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M |
| Stockholders Equity | 38.17M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
Cash Flow | ||||||
| Free Cash Flow | -34.03M | -26.42M | -29.31M | -21.05M | -14.09M | -9.05M |
| Operating Cash Flow | -33.97M | -26.39M | -14.56M | -21.05M | -13.55M | -8.80M |
| Investing Cash Flow | -6.56M | -2.03M | -14.76M | 0.00 | -536.84K | -250.00K |
| Financing Cash Flow | 0.00 | -15.27K | 109.29M | 0.00 | -102.07K | 58.39M |
Context Therapeutics Technical Analysis
Negative
0.44
Price Trends
0.44
Negative
0.90
Negative
1.57
Negative
Market Momentum
-0.04
Negative
30.68
Neutral
10.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.35, below the 50-day MA of 0.44, and below the 200-day MA of 1.57, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 30.68 is Neutral, neither overbought nor oversold. The STOCH value of 10.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTX.
Context Therapeutics Risk Analysis
Context Therapeutics disclosed 61 risk factors in its most recent earnings report. Context Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Context Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $210.93M | -3.30 | -53.89% | ― | -100.00% | -1813.57% | |
44 Neutral | $28.45M | -0.64 | -82.06% | ― | ― | -23.49% | |
43 Neutral | $29.70M | -0.42 | -413.28% | ― | ― | 43.02% | |
42 Neutral | $191.36M | -6.04 | -29.09% | ― | 8906.15% | 41.48% | |
33 Underperform | $13.05M | -2.09 | -64.46% | ― | ― | 33.15% |
* Healthcare Sector Average
CNTX
Context Therapeutics
0.31
-0.90
-74.46%
WHWK
Whitehawk Therapeutics
3.70
1.55
72.09%
QNCX
Quince Therapeutics
29.20
-360.80
-92.51%
ADAG
Adagene
2.85
0.86
43.22%
ANEB
Anebulo Pharmaceuticals
0.32
-2.01
-86.27%
Context Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
Positive
Aug 5, 2026
On August 5, 2026, Context Therapeutics updated its corporate presentation to outline progress and plans for its T cell engager pipeline, emphasizing CTIM-76 and CT-202 as key bispecific antibody programs for solid tumors such as platinum-resistan...
Delistings and Listing ChangesRegulatory Filings and Compliance
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
Negative
Jul 31, 2026
On July 29, 2026, Context Therapeutics Inc. received a notification from Nasdaq that its common stock was no longer in compliance with the Minimum Bid Price Rule, having closed below $1.00 per share for 30 consecutive business days. The notice doe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.